At one point, it was Europe's most valuable company.

Now, as Danish pharmaceutical group Novo Nordisk prepares to publish its third-quarter earnings on Wednesday, the picture looks very different.

CNBC's Charlotte Reed will travel to Copenhagen to speak with the company's new CEO Mark Doustdar, a 30-year veteran of the company, who has been in the top job since August.

It's not been an easy ride so far, with the group announcing a sharp decline in sales, pressure on profit, a round of jobs cuts and continued competition from U.S. rivals when it comes to the blockbuster obesity drug market.

Analysts' views

Despite this, Berenberg is positive on the stock, saying Novo has hit "peak uncertainty."

"Novo's superior growth profile and best-in-class R&D returns warrants a higher

See Full Page